TY - JOUR
T1 - Clinical and biochemical spectrum of D-bifunctional protein deficiency
AU - Ferdinandusse, S
AU - Denis, S
AU - Mooyer, PAW
AU - Dekker, C
AU - Duran, M
AU - Soorani Yancheshmeh - Lunsing, Roelineke
AU - Boltshauser, E
AU - Macaya, A
AU - Gartner, J
AU - Majoie, CBLM
AU - Barth, PG
AU - Wanders, RJA
AU - Poll-The, BT
PY - 2006/1
Y1 - 2006/1
N2 - Objective D-bifunctional protein deficiency is an autosomal recessive inborn error of peroxisomal fatty acid oxidation. Although case reports and small series of patients have been published, these do not give a complete and balanced picture of the clinical and biochemical spectrum associated with this disorder. Methods. To improve early recognition, diagnosis, prognosis, and management of this disorder and to provide markers for life expectancy, we performed extensive biochemical studies in a large cohort of D-bifunctional protein-deficient patients and sent out questionnaires about clinical signs and symptoms to the responsible physicians. Results: Virtually all children presented with neonatal hypotonia and seizures and died within the first 2 years of life without achieving any developmental milestones. However, within our cohort, 12 patients survived beyond the age of 2 years, and detailed information on 5 patients with prolonged survival (>= 7.5 years) is provided. Interpretation Biochemical analyses showed that there is a dear correlation between several biochemical parameters and survival of the patient, with C26:0 beta-oxidation activity in cultured skin fibroblasts being the best predictive marker for life expectancy. Remarkably, three patients were identified without biochemical abnormalities in plasma, stressing that D-bifunctional protein deficiency cannot be excluded when all peroxisomal parameters in plasma are normal.
AB - Objective D-bifunctional protein deficiency is an autosomal recessive inborn error of peroxisomal fatty acid oxidation. Although case reports and small series of patients have been published, these do not give a complete and balanced picture of the clinical and biochemical spectrum associated with this disorder. Methods. To improve early recognition, diagnosis, prognosis, and management of this disorder and to provide markers for life expectancy, we performed extensive biochemical studies in a large cohort of D-bifunctional protein-deficient patients and sent out questionnaires about clinical signs and symptoms to the responsible physicians. Results: Virtually all children presented with neonatal hypotonia and seizures and died within the first 2 years of life without achieving any developmental milestones. However, within our cohort, 12 patients survived beyond the age of 2 years, and detailed information on 5 patients with prolonged survival (>= 7.5 years) is provided. Interpretation Biochemical analyses showed that there is a dear correlation between several biochemical parameters and survival of the patient, with C26:0 beta-oxidation activity in cultured skin fibroblasts being the best predictive marker for life expectancy. Remarkably, three patients were identified without biochemical abnormalities in plasma, stressing that D-bifunctional protein deficiency cannot be excluded when all peroxisomal parameters in plasma are normal.
KW - PEROXISOMAL BETA-OXIDATION
KW - CHAIN FATTY-ACIDS
KW - PSEUDO-ZELLWEGER SYNDROME
KW - COA HYDRATASE DEFICIENCY
KW - HUMAN SKIN FIBROBLASTS
KW - PRISTANIC ACID
KW - MULTIFUNCTIONAL PROTEIN-2
KW - DOCOSAHEXAENOIC ACID
KW - BIOGENESIS DISORDERS
KW - GAS-CHROMATOGRAPHY
M3 - Article
SN - 0364-5134
VL - 59
SP - 92
EP - 104
JO - Annals of Neurology
JF - Annals of Neurology
IS - 1
ER -